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Abstract: Low molecular weight opioid peptide esters (OPE) could become a class of analgesics with different side effect profiles than 
current opiates. OPE may have sufficient plasma stability to cross the blood brain barrier (BBB), undergo ester hydrolysis and produce 
analgesia. OPE of dipeptides, tyr-pro and tyr-gly conjugated to ethanol have a structure similar to the anesthestic agent, etomidate. 
Based upon the analgesic   activity of dipeptide   opioids, Lipinski’s criteria, and permeability of select GABA esters to cross the BBB, 
opioid peptides (OP) conjugated to ethanol, cholesterol or 3-  glucose are lead recommendations. Preliminary animal data suggests that 
tyr-pro-ethyl ester crosses the BBB and unexpectedly produces   hyperalgesia. Currently, there are no approved OP analgesics available 
for clinical use. Clinical trials of good manufacturing practice OP administered to patients suffering from chronic pain with indwelling 
intrathecal pumps could resolve the issue that OP may be superior to opiates and may redirect research.
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Hypothesis
It is hypothesized that an ester comprised of a low 
molecular weight opioid peptide (OP) and a   lipophilic 
moiety that is non toxic to the central nervous   system 
can  be  parentally  absorbed  and  produce  a  plasma 
level sufficient to cross the blood brain barrier (BBB) 
(in spite of peptidases and esterases in the plasma). 
The OP with a lipophilic moiety, opioid peptide ester 
(OPE),  can  be  hydrolyzed  by  spinal  fluid  esterase 
liberating  an  OP  which  produces  analgesia.  The 
side effect profile of the OPE including tolerance, 
addiction  and  opioid  hyperalgesia  may  be  distinct 
from  present  opiates  due  to  structural  differences 
between the two classes of compounds. The proof of 
this concept can be obtained by conducting a clini-
cal trial, preceded by animal studies, in which there 
is intrathecal administration of OP made according 
to  good  manufacturing  practice  (GMP)  in  patients 
who  have  indwelling  intrathecal  pumps. Although 
expensive, the results of such a trial could be pivotal 
for redirecting OP research.
Introduction
For centuries opioids derived from the poppy plant 
have been the mainstay of therapy for acute pain. In 
the last few decades, opioid analgesics have become 
the primary medications for the treatment of intrac-
table chronic pain. As our experience with this therapy 
increases, we have learned that in some patients the 
use of chronic opioid therapy has brought on a new 
set of problems. These include tolerance, addiction, 
pseudo-addiction, opioid induced hyperalgesia, bowel 
dysfunction,  suppression  of  testosterone,  cognitive 
impairment,  substance  abuse  and  diversion.1  The 
most serious complication of chronic opioid therapy 
is  the  rising  incidence  of  death  from  respiratory 
depression  as  a  consequence  of  drug  overdose  of 
prescribed  opioids.2,3  Some  medication  specific 
problems  include  prolongation  of  the  QT  interval 
from  methadone,4–6  seizures  from  normeperidine, 
a  metabolite  of  meperidine,7,8  convulsions  from 
morphine-3 glucoronide, a metabolite of morphine,9 
and fluctuating bioavailability from use of transdermal 
fentanyl.10–12
Opioid tolerance
The cause of opioid tolerance is not well understood. 
There are some patients who develop tolerance after 
minimal exposure, while others may become tolerant 
over many months and others never develop tolerance 
to the medication. Although tolerance to short term 
administration of intrathecal beta endorphin has been 
reported, it is not known whether tolerance will occur 
with long term treatment with an OP.13 The following 
is support of the proposition that tolerance to OP may 
be different than tolerance to opiates: (1)   Endogenous 
opioids promote mu receptor   internalization through 
endocystosis which is lacking in narcotic   analgesics.14 
Endocytosis  closely  regulates  morphine  receptor 
transduction and inhibits desensitization which leads 
to tolerance.14 (2) In vitro studies show that the more 
efficient  an  agonist  binds  to  the  mu  receptor  the 
less likely that tolerance will occur.15 The OP may 
bind more efficiently than opiates to the mu recep-
tor because the structure of the OP is different and 
lacks the piperidine ring found in morphine and its 
  derivatives.16  (3)  Similar  to  many  hormones,  OP 
couple to G protein receptors for activity. After the 
onset of clinical symptoms, tolerance to the hyper-
secretory effects of other endogenous hormones that 
occur in disease states such as Cushing’s syndrome 
and   disease, pheochromocytoma, and carcinoid syn-
drome is exceedingly rare, a mechanism of action that 
could be shared with OP.17
respiratory depression
It has been shown that endomorphins 1 and 2, which 
are  potent  OP  that  have  high  affinity  for  the  mu 
receptor,  produce  less  respiratory  depression  than 
comparable doses of morphine.18 Also OP may have a 
higher threshold for producing respiratory depression 
than opiates.18
Opioid hyperalgesia, addiction  
and bowel dysfunction
Because  the  creation  of  an  OPE  which  can  cross 
the BBB would be a novel class of medications it 
is not known and there is little data even to specu-
late whether chronic treatment with an OP will have 
adverse  effects  similar  to  opiates  and  whether  OP 
induced hyperalgesia and addiction will occur.19,20 In 
animal models, endomorphins inhibit gastric empty-
ing time and decrease intestinal propulsion suggest-
ing  bowel  dysfunction  may  occur. Therefore,  it  is 
unlikely that the use of an OPE will eliminate all the 
current side effects of opiate therapy.Low molecular weight opioid peptide esters
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Obstacles for development of OPe
The  development  of  synthetic  opioids,  such  as, 
  fentanyl, meperidine, and methadone has improved 
the  bioavailability,  potency,  and  to  some  degree 
the side effects profile of analgesics. However, OP 
  analgesics have not been developed for clinical use, 
even though their discovery occurred in the 1970s.21 
One of the major obstacles in the development of an 
OPE has been developing a stable medication that 
can cross the BBB.22,23 More specifically some of the 
impediments can be listed:
1. Identifying lead compounds
2. Synthesis
3. Bioavailability
4. Stability from plasma peptidases and esterases
5. Crossing the BBB
6. Hydrolysis in the cerebral spinal fluid (CSF) to lib-
erate an active opioid peptide
7. Efflux from the central nervous system (CNS)
1. Identifying Lead compounds
Molecular size is a significant factor in determin-
ing  whether  a  medication  will  cross  the  BBB. 
  Medications that have a size greater than 400–600 
Daltons are unlikely to cross the BBB.24,25 Although 
in the past, the literature showed that tetrapeptides 
were the smallest active OP26 newer literature sug-
gests that smaller OP containing two amino acids are 
analgesics. There is experimental evidence that the 
two dipeptides, tyr-pro and tyr-gly can produce dose 
related  analgesia  that  is  reversed  by  naloxone.27,28 
The structure of tyr-pro and try-gly could assume an 
active conformation of an aromatic and virtual het-
ereocylic (piperazine like) ring which in theory may 
be related to analgesia.16
Ethanol,  cholesterol  and  3-glucose  are  possible 
conjugates which can be used to form the lead OPE. 
OPE of ethanol are particularly attractive because of 
the structural resemblance to etomidate which rap-
idly enters the CNS after intravenous administration 
(Fig. 1, 2). All of these compounds are “familiar” 
within the CNS. Although D amino acids have been 
substituted in many OP because of increased stability 
and potency (DAMGO, DALDA) these introduce a 
metabolite which is foreign to the central nervous 
system.  Cholesterol  esters  of  the  neurotransmitter 
GABA penetrate the BBB with ease and one can expect 
the same with small OPE made with cholesterol.29 
Another way which can facilitate transport through 
the BBB would be by using the glucose transport 
system. An example is the 3-glucose ester of GABA 
that  is  not  nearly  as  lipophilic  as  the  cholesterol 
ester but is still able to have a high brain penetra-
tion  index  (BPI)  because  of  probable  transport  by 
GLUT-1  transporter.30  OPE  of  ethanol,  cholesterol 
and 3-glucose may theoretically be reasonable lead 
compounds, however, the gold standard for BBB per-
meability still requires an in vivo bioassay.
2. synthesis
In the literature, there are cited examples of biologi-
cally  active  esters  that  have  been  synthesized  and 
these can be used as a guide for developing OPE. 
In  the  1980s,  Shashoua  synthesized  many  GABA 
ester analogs through condensation reactions of the 
  carboxylic acid of GABA and alcohol conjugates in 
an acidic environment.30 It would be expected that the 
NH2 terminal portion of the OP would need to be pro-
tected with a t-BOC derivative that would be cleaved 
after  ester  synthesis. A  more  lipophilic  compound 
would more likely be made if the OH of tyrosine 
were acetylated, similar to the way heroin is made 
more lipophilic and thus crosses the BBB more   easily 
than morphine. However, the synthesis carries risk 
of breaking peptide bonds from the energy required 
to  complete  the  ester  condensation(s).  The  energy 
required for formation of the of ester condensation(s) 
O
O
N
N
Figure 1. etomidate.
O O
O
O
N
N
H
H
H
Figure 2. Tyr-pro-ethyl ester.Goldberg
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is lower than that for disruption of various peptide 
bonds as estimated by Martin,31 but extreme care may 
need to be taken when heating the mixture or   consider 
using stabilizers such as cesium salts.32 Various OP 
are  commercially  available  and  fragments  can  be 
obtained using methods described in the literature. 
This author believes that OPE of ethanol,   cholesterol 
and  3-glucose  can  be  synthesized  and  purified  to 
  conduct biologic trials.
3. Bioavailability
Until  a  novel  enteric  coating  is  developed,  it  is 
unlikely  that  OPE  can  be  absorbed  through  the 
gastrointestinal tract because of gastric acidity and 
digestive  enzymes.  The  formulations  of  OPE  that 
could be absorbed are parental through transdermal, 
subcutaneous, intramuscular or intravenous routes.
4. plasma stability
Once the OPE enters the plasma, it would be exposed 
to hydrolysis from plasma esterases and peptidases. 
The  actions  of  these  enzymes  would  enhance  the 
degradation of the OPE and would be difficult to 
block. Endomorphin 1 and 2 which are tetrapeptides 
have been shown to have a very short half-life in 
plasma with the early degradation occurring between 
the  second  and  third  amino  acids.  The  first  two 
amino acids in the endomorphins are tyr-pro and this 
peptide bond is somewhat protected from degradation 
by proline. It takes five hours for aminopeptidase 
to degrade the dipeptide in vitro.33,34 This  amount 
of time would seem sufficient for the OPE to cross 
the BBB.
On  the  other  hand,  the  ester  bond  in  the  OPE 
would be more likely to break from plasma esterases. 
  However,  ester  hydrolysis  in  the  plasma  does  not 
preclude effective OPE activity, because the rates of 
hydrolysis may be less than the rate of permeability 
across the BBB. For example, ester local   anesthetics 
which  are  rapidly  hydrolyzed  in  the  plasma  can 
  produce  pronounced  CNS  effects  with  as  little  as 
60 mg given intravenously in an average size patient 
and etomidate, an ester of ethanol, is a rapid induction 
agent.35
5. crossing the BBB
Some of these considerations were discussed in #1 
Indentifying  lead  compounds.  Besides  molecular 
size,  lipophilic  properties,  charge  and  propensity 
for  hydrogen  bonding  are  also  important  factors 
restricting  a  molecule  from  crossing  the  BBB.36 
  Cholesterol used as a conjugate can increase the lipo-
philic properties of the OP. The ester formation cre-
ated with   cholesterol will change the OP charge from 
a zwitterion to that of a single cationic charge on the 
terminal  amine  thus  favoring  penetration  through 
the BBB. Because the amine of tyrosine is a weak 
base and the CSF (pH ∼7.3) is more acidic than the 
plasma (pH 7.4), ion trapping will occur increasing 
concentrations of the OPE in the CSF.16 As previously 
mentioned, the OH of tyrosine could form hydrogen 
bonds within the brain capillary endothelium imped-
ing movement across the BBB and therefore esteri-
fication may be required to facilitate transfer across 
the BBB.   Preliminary observations with tyr-pro-ethyl 
ester (See Experimental section) suggest that this may 
not be the case. Other methods, reported in the litera-
ture, to enhance permeation of OP across the BBB 
include: cyclic prodrugs, viral vectors, fusion pro-
teins, peptide and nutrient transport   systems,   Trojan 
horse vectors, and nanoparticles.18,37–39   Compared to 
these methods, ester prodrugs are simpler to synthe-
size and have been demonstrated clinically to cross 
the BBB.
6. Hydrolysis of Ope in the cns
Esterases are well known to exists in the CSF and 
these could beneficially hydrolyze the OPE.40,41 In 
comparison, peptidases may not be as plentiful as 
Table 1. Molecule weights and potential hydrogen bonding 
of constituents of possible OPe.
M.W H bond  
donor  
(n+O)H
H bond   
accept  
(n+O)
Tyr-gly 238 4 5
Tyr-pro 278 2 4
Tyr-gly-gly 295 5 6
Try-gly-gly-ph 442 6 7
Tyr-gly-gly-phe-leu 556 7 8
Tyr-pro-phe-phe-NH2  
(endomorphin-2)
572 5 6
Tyr-pro-trp-phe-NH2  
(endomorphin-1)
611 6 6
ethanol 46 1 1
Cholesterol 387 1 1
3-glucose 180 5 6Low molecular weight opioid peptide esters
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esterases in the CSF. In animal CSF,   endomorphin 
1  and  2  have  been  shown  to  be  remarkably 
stable.33,42
7. Efflux from the CNS
Active transporters have been described that may serve 
to protect the CNS from toxic substances including 
metabolites.  Two  non-synthetic  OP  (  endomorphin 
1 and 2) have been shown to be   transported out of 
the  brain  presumably  through  an  efflux    system.33 
  However, an OP transporter has not been as yet dis-
covered  and  at  the  present  time  termination  of  an 
opioid  peptide  is  primarily  thought  to  occur  from 
redistribution and degradation.
Had the above problems been easy to solve and 
benefits proven, an OP would likely have been deve-
loped  decades  ago.  However,  the  potential  reward 
of  an  OP  analgesic  with  improved  analgesia  and 
less side effects still remains speculative. All things 
considered, many in the field (as estimated by the 
number  of    publications  in  this  area)  believe  that 
resources should be devoted to developing a clinically 
effective OP.
Physical and chemical properties  
of potential leads
Low molecular weight opioid peptides are listed in 
ascending  order.  Potential  hydrogen  bond  donors 
(N+O with one or more H) and potential hydrogen 
bond acceptors (N+O) for each potential OP are listed 
as well as physical and chemical   properties of the 
possible ester conjugates, glucose and   cholesterol.24 
Table 1. The BPI and Kow of GABA   conjugated esters 
of  cholesterol  and  3-Glucose  are  listed.43  Table  2. 
Possible  lead  OPE  compounds  are  listed. Table  3. 
Lipinski’s criteria for drug like properties and modifi-
cations for CNS penetration are listed. Table 4.
While the above leads compounds do not precisely 
fit any of the Lipinski’s criteria there may be enough 
interest to stimulate further development. It is worth 
reiterating:
1. Our experience with ester local anesthetics and 
etomidate teaches us that significant CNS pen-
etration can occur even with rapid plasma ester 
hydrolysis. Preliminary animal data suggests that 
tyr-pro-ethyl ester crosses the BBB and unexpect-
edly  produces  hyperalgesia.  (See  Experimental 
Section)
2. The tyr-pro is protected and unlikely to be rapidly 
hydrolyzed in the plasma.
3. The  ideal  OPE  would  be  comprised  of  an  OP 
and conjugate that aids crossing the BBB and be 
acceptable to introduce into the CNS. The above 
conjugates of ethanol, 3-glucose and cholesterol 
were  chosen  because  they  have  been  shown  in 
animal models to facilitate crossing of the BBB 
or  they  are  also  “familiar”  and  relatively  non-
toxic to the CNS at predicted concentrations. OP 
conjugates of ethanol look particularly attractive 
because of similar structure and molecular weight 
as etomidate which rapidly produces CNS effects 
after intravenous administration.
4. Glucose  is  probably  actively  transported  across 
the BBB so some aspects of the above criteria may 
not be applicable.
Table  2.  GABA  ester  lipid/water  partition  coefficients 
and BPi.
BpI Kow
Cholesteryl-GABA 25 110
3-Glucosyl-GABA 104 0.21
Table 3. Lead OPe compounds to consider for in vivo trials. 
MW H bonds  
donor*  
(n+O)H
H bond  
acceptor*  
(n+O)
pKa
1. ethyl-pro-Tyr 306 3 5 9.1
2. ethyl-gly-Tyr 266 1 4 9.1
3. 3-Glucosyl-pro-Tyr 440 6 9 9.1, 12.8
4. Cholestryl-pro-Tyr 647 2 4 9.1
5. 3-Glucosyl-gly-Tyr 432 8 10 9.1, 12.8
6. Cholestryl-gly-Tyr 607 4 5 9.1
note: *Assumes the OH in tyr is not acetylated.Goldberg
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5. Some other “familiar” conjugates would be dehy-
droascorbic acid and diethylaminoethanol.43
6. It  may  be  reasonable  to  spend  some  collective 
resources on clinical trials of GMP OP in patients 
suffering from intractable pain rather than totally 
on laboratory development.
The clinical view of OPe
It remains speculation whether OP will offer any 
advantages over opiates for the treatment of chronic 
pain.  Experience  delivering  OP  for  chronic  pain 
to  humans  and  animals  is  limited.  Many  papers 
have  been  published  assuming  and  speculating 
that    discovering  a  bioavailable  central  acting  OP 
is a   worthy goal.   However, the capacity to answer 
this question is within our reach if OP, preferably 
natural    products  familiar  to  the  CNS,  such  as 
leu-enkephalin,  and  endomorphin  1  and  2  were 
manufactured    according  to  GMP  so  that,  after 
appropriate animal studies,   clinicians could conduct 
clinical trials in patients suffering intractable pain 
Table 5. Cold immersion experiment.
pre-dosing
Date: 6/30/2011
Animal ID Trial 1 Trial 2 Trial 3 Mean sD
Time Latency Time Latency Time Latency
1 1408 17.8 1419 18 1434 16.8 17.5 0.6
2 1405 7.4 1417 5.6 1432 8.4 7.1 1.4
3 1409 14.2 1420 9.8 1435 9.7 11.2 2.6
eliminating the longest latency period, means are as follows
Animal ID Mean sD
1 17.3 0.7
2 6.5 1.3
3 9.8 0.1
Date: 7/1/2011
Animal ID Dosage  
(1 ml)
Time of  
dosing
1 1 mg 1333
2 2 mg 1334
3 0.5 mg 1331
post-dosing
Date: 7/1/2011
Animal ID Trial 1 Trial 2 Trial 3 Mean sD
Time Latency Time Latency Time Latency
1 1358 13.2 1409 22.1 1421 11.5 15.6 5.693
2 1400 4.7 1411 4.7 1422 12.2 7.2 4.3301
3 1357 6.45 1408 6.2 1423 9.0 7.2167 1.5495
eliminating the longest latency period, means are as follows
Animal ID Mean sD
1 12.4 1.2
2 4.7 0.0
3 6.3 2.0
Table 4. Lipinski’s criteria for drug properties.
Lipinski’s rule of 524 Lipinski’s modification 
for cns penetration44
Kow ,5 Kow ,5
Molecular weight ,500 Molecular weight ,400
H-bond donors ,5 H-bond donors ,3
H bond acceptors ,10 H-bond acceptors ,7Low molecular weight opioid peptide esters
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who have indwelling intrathecal pumps and thus the 
BBB is bypassed.
experimental section
This investigation was approved by the Institutional 
Animal  Care  and  Use  Committee  of  the  Durham 
  Veterans Affairs Medical Center and was conducted 
by Dr. Jem Scott-Emuakpor of the Durham Veterans 
Affairs Medical Center.
Methods
Three male Wistar rats at 8 weeks of age (Taconic 
Farms, Germantown, NY) were utilized in the experi-
ment. Each rat was grasped firmly, while the distal 
half of its tail was immersed in a liquid bath at a tem-
perature of −20 °C. Latency periods (in seconds) were 
measured from the time that tails were immersed to the 
time that the rat removed its tail from the liquid. Prior to 
dosing, rats were given three trials, approximately ten 
minutes apart. On the   following day, rats were given 
i.p. doses (0.5 mg, 1 mg, 2 mg) of   Tyr-pro-ethyl ester 
(Genscript, Piscataway, NJ) and, after thirty minutes, 
another three trials were conducted. Post-dose trials 
were also, approximately ten minutes apart.   Animals 
were examined for acute adverse effects to both the 
cold liquid bath and the test article.
results (Table 5)
interpretation
Data suggests that, at the doses given, Tyr-pro-ethyl 
ester may have some neurological effects on rats and 
that it may, in fact, increase sensitivity to noxious 
stimulus. However, given the limited data that can 
be collected from so few test subjects, it is difficult 
to say whether the rats experienced greater sensitiv-
ity to cold or whether they were more sensitive to 
handling.
conclusion
Historically, many attempts to improve present opi-
ates for long term treatment of intractable pain have 
failed. Morphine and methadone continue to remain 
the most commonly prescribe opioids in chronic pain 
clinics. An OP, targeting the mu receptor for long 
term control of pain, has not been accomplished due 
a  number  of  difficulties  particularly  developing  a 
compound that can cross the BBB. A number of the 
roadblocks such as plasma and CNS stability have 
been  discussed.  However,  as  minimal  size  opioids 
have been discovered that can be ester conjugated to 
lipophilic groups, the possibility of a successful opi-
oid peptide analgesic is increased. Preliminary data in 
rats suggest that tyr-pro-ethyl ester crosses the BBB 
and may produce hyperalgesia and larger OPE may 
be pharmacologically active. Once the active OPE is 
developed, the next step would be to determine if it 
has more favorable qualities than opiates. Clinical tri-
als of OP manufactured according to GMP in patients 
with indwelling intrathecal pumps could provide the 
answer to this very important question.
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